|
News was released after the market close
today.
Those members that took our advice over the weekend to keep a keen
eye on PSiV today are obviously happy they did. Up
over 85%! Tomorrow we urge you to keep the watch. Being news was
released after the close, tomorrow could prove even more exciting than
today.
Here's the News released just moments
ago. Important news for PSiV..
Pacific Sunset Investments Signs
Agreement With Advanomics -- Support and Lab Services
Monday July 25, 4:21 pm ET Go to yahoo or any financial site
to read the news now!
BioTechnology
News..... Tomorrow watch again.. Radar Alert
Pacific Sunset Investments
Inc.
PSiV
How many times have you
heard about this????
adverse drug reactions accounted for more than
2.2 million serious cases and over 100,000 deaths,
Given a choice, if possible, wouldn't you want a
test to make sure you didn't suffer a deadly reaction to a prescribed drug
first?
PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV
A study published in the Journal of the American Medical
Association reported that adverse drug reactions accounted for more than 2.2
million serious cases and over 100,000 deaths, making adverse
drug reactions (ADRs) one of the leading causes of hospitalization and death in
the United States.
Breaking News
for Pacific Sunset Investments
Pacific Sunset Investments
Completes Gen ID Acquisition
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--May 20,
2005--Pacific Sunset Investments, Inc. ("Pacific Sunset") (OTC:PSiV announced
that it has completed its acquisition of Gen-ID Lab Services, LLC, a California
limited liability corporation specializing in Single Nucleotide Polymorphism
analysis data. In addition, the board of directors of Pacific Sunset has
appointed Douglas Freedman to its board of directors with experience in
marketing. Additionally, the company has appointed Dr. Steve N. Slilaty, Ph.D.,
to head an Advisory Board to assist the company with reviewing new alternatives
in the "SNP" field of technology.
Gen ID will provide "SNP" (Single
Nucleotide Polymorphism) analysis data. The results of SNP analysis provide
physicians with a more enlightened choice of drugs and they will also be able to
predict the effectiveness of the drugs for individual patients. The use of an
SNP test to help treat childhood leukemia is currently being used by doctors and
hospitals in the United States.
Dr. Steve Slilaty is President
and Chief Scientific Officer of Advanomics Corporation, a leading-edge
biotechnology company focusing on the identification of disease related
molecular targets using advanced transriptomics technologies, which he recently
developed. Dr. Slilaty also is an Adjunct Professor at the Universite du Quebec
in the department of Microbiology and Biotechnology. Dr. Slilaty has founded
three biotechnology companies, Advanomics Corporation, Quantum Biotechnologies
Inc. (now known as Qbiogene Inc.) and Geneomics One Corporation. In addition,
Dr. Slilaty is one of the pioneers of Gene Therapy, having developed the first
Gene Transfer system in 1983.
(This is a partial clip of the news.
We suggest you go read the whole release. Our opinion is, this is
important technology. Go to yahoo or any financial site and read the
news)
CONCLUSION:
adverse drug reactions accounted for more than
2.2 million serious cases and over 100,000 deaths,
Doesn't this say it all?
A company to
watch!
AGGRESSIVE INVESTORS TAKE NOTE NOW! PUT Pacific Sunset Investments Inc. PSiV ON YOUR RADAR SCREENS NOW, AND WATCH THIS COMPANY STARTING NOW This email was prepared based upon public information
believed to be reliable. The information contained herein is not guaranteed
by us to be accurate, and should not be considered to be all-inclusive. The
company that we discussed in this opinion has not approved the
statements made in this opinion. This opinion contains forward-looking
statements that involve risks and uncertainties. This company like many on
the bulletin boards and pink sheets does have an accumulated deficit since
inception, has relied on loans from officers and directors, does have an
auditors on going concern, has a nominal cash position and has no revenue or
nominal revenues in its most recent quarter This material is for
informational purposes only and should not be construed as an offer or
solicitation of an offer to buy or sell securities. Be aware We are not a
licensed broker, broker dealer, market maker, investment banker, investment
advisor, analyst or underwriter. Please consult a broker before purchasing or
selling any securities mentioned herein. Be aware that we are paid
for these advertisements. We have been compensated by third party
shareholders or with cash from the company on behalf of one or more of the
companies mentioned in this opinion. Liquid Assetts is the third party.
We have been compensated two hundred thousand free trading shares
for advertising psiv. We are expecting an additional ninty four thousand
shares in the near future. We do intend to sell all shares. In
addition to any compensation mentioned above, additional compensation can be
equal to ten percent of any newly issued or registered securities of the
profiled companies. Our affiliates, officers, directors and employees may
also have bought or may buy the shares discussed in this opinion and may profit
in the event those shares rise in value. We will not advise as to when it
decides to sell and does not and will not offer any opinion as to when others
should sell; each investor must make that decision based on his or her judgment
If you are not a savy investor and are not familiar with the violatile
movements in many Bulletin Board and pinksheet stocks, we suggest you sit back
and watch, you can lose all your money very quickly. To
permanently stop receiving thisNewsletter, please use our secure One-Step
Safe Un-Sub-scribe: Send a blank e-mail with "NoThanks" in the
sub-ject line to [EMAIL PROTECTED] For any questions, comments or
complaints about receiving this
SPONSORED LINKS
YAHOO! GROUPS LINKS
|
